A 3-year-old girl was brought to Department of Obstetrics and Gynecology for breast development and excessive vaginal discharge. Her medical history and family history were unremarkable. From investigations she was diagnosed as a case of precocious puberty. This case report emphasized how this condition should be evaluated and how the girl was managed. 
Introduc
mg every 4 weeks. Now she is 3 years old. The drug is to be continued for 11 years of her age. After giving treatment follow up was done after one month. At that time she developed menstruation which remains for 2 days. Pelvic and axillary hair increases. But when she came after 2 months her breast size decreases and menstruation not appeared. We advised the guardian to come every month for taking inj. GnRH agonist up to 11 years of her age.
Discussion
In the case described, we have found advanced breast development, pubic and axillary hair development. Her height was within normal limit. She had excessive vaginal discharge and at one time the patient had menstruated. Evidence of possible causes of precocious puberty was sought by means of thorough history taking and careful examination. In her personal history and family history nothing contributory was noted. Level of sex steroid should be determined. In girls, serum estradiol level is highly variable but low sensitivity for diagnosis of precocious puberty 5 . Random measurement of luteinizing hormone has been proposed. In one study randomly measured value 0.3 IU per liter and above were reported to be 100% specific 6 .
In our case serum estradiol and LH level were elevated. A reference atlas such as the one Gy Greulich to evaluate the effect of sex steroid on epiphyseal maturation. The bone age is greater than chronological age 7. Bone age is greater than chronological age is also in this case. A study showed that to perform GnRH agonist stimulation test to further evaluate the activation of gonadotrophin axis and the potential for progression of puberty 8. There are no facilities in our institution for GnRH agonist stimulation to see the progression of puberty. Several report showed that MRI scan did not show no CNS lesion in approximately 92% of girls 9 . This girls also has no abnormalities on MRI. Most common mechanism of progressive or central precocious puberty is the early activation of pulsatile gonadortropin releasing hormone which may result from hypothalamic tumour or lesion but in most cases remain unexplained 10 . Several report showed that constitutional type is the commonest but rare is to be kept in mind. However in our patient from history with various investigations we come to conclusion this is a case of precocious puberty central type. In open label, non comparative longitudinal studies, the use of GnRH agonists consistently resulted in the regression or stabilization of pubertal symptoms 11 .
There are many options of medication medroxy projesterone acetate, cyproterone acetate and letrozole. Pubertal manifestation generally reappair within months after GnRH agonist treatment has been stopped. With a mean time to menarche of 16 months. Long term fertility has not been fully evaluated but preliminary observation are reassuring 12 .
The availability, approved use, recommended dosages of depot GnRH agonist vary through out the world. We use inj. Triptorelin 3.75mg every 4 weeks up to 11 years at her age. Prognosis of this patient is good. No such side effect of drug detected in this patient.
